Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $428.65 million. The enterprise value is $169.53 million.

Market Cap	428.65M
Enterprise Value	169.53M

Important Dates

The next estimated earnings date is Friday, May 8, 2026, before market open.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 15.62 million shares outstanding. The number of shares has increased by 21.40% in one year.

Current Share Class	15.62M
Shares Outstanding	15.62M
Shares Change (YoY)	+21.40%
Shares Change (QoQ)	+4.32%
Owned by Insiders (%)	10.18%
Owned by Institutions (%)	56.22%
Float	5.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.61
P/TBV Ratio	1.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.56, with a Debt / Equity ratio of 0.04.

Current Ratio	16.56
Quick Ratio	16.42
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-20,641.60

Financial Efficiency

Return on equity (ROE) is -31.41% and return on invested capital (ROIC) is -21.59%.

Return on Equity (ROE)	-31.41%
Return on Assets (ROA)	-20.66%
Return on Invested Capital (ROIC)	-21.59%
Return on Capital Employed (ROCE)	-37.92%
Weighted Average Cost of Capital (WACC)	14.33%
Revenue Per Employee	n/a
Profits Per Employee	-$689,702
Employee Count	131
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +78.13% in the last 52 weeks. The beta is 1.89, so Neurogene's price volatility has been higher than the market average.

Beta (5Y)	1.89
52-Week Price Change	+78.13%
50-Day Moving Average	21.89
200-Day Moving Average	21.76
Relative Strength Index (RSI)	66.16
Average Volume (20 Days)	160,270

Short Selling Information

The latest short interest is 4.01 million, so 25.69% of the outstanding shares have been sold short.

Short Interest	4.01M
Short Previous Month	4.03M
Short % of Shares Out	25.69%
Short % of Float	78.00%
Short Ratio (days to cover)	26.23

Income Statement

Revenue	n/a
Gross Profit	-74.89M
Operating Income	-103.21M
Pretax Income	-90.35M
Net Income	-90.35M
EBITDA	-100.12M
EBIT	-103.21M
Earnings Per Share (EPS)	-$4.24

Full Income Statement

Balance Sheet

The company has $269.01 million in cash and $9.89 million in debt, giving a net cash position of $259.12 million or $16.59 per share.

Cash & Cash Equivalents	269.01M
Total Debt	9.89M
Net Cash	259.12M
Net Cash Per Share	$16.59
Equity (Book Value)	264.89M
Book Value Per Share	17.10
Working Capital	255.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$77.17 million and capital expenditures -$1.18 million, giving a free cash flow of -$78.36 million.

Operating Cash Flow	-77.17M
Capital Expenditures	-1.18M
Depreciation & Amortization	3.09M
Net Borrowing	-61,000
Free Cash Flow	-78.36M
FCF Per Share	-$5.02

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.40%
Shareholder Yield	-21.40%
Earnings Yield	-21.08%
FCF Yield	-18.28%

Analyst Forecast

The average price target for Neurogene is $63.57, which is 131.59% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$63.57
Price Target Difference	131.59%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1